tetano
Editor, Senior Moderator
Clin Infect Dis
. 2021 Jan 3;ciaa1927.
doi: 10.1093/cid/ciaa1927. Online ahead of print.
Effectiveness of Influenza Vaccine for Preventing Laboratory-Confirmed Influenza Hospitalizations in Immunocompromised Adults
Kailey Hughes[SUP] 1 [/SUP], Donald B Middleton[SUP] 1 2 [/SUP], Mary Patricia Nowalk[SUP] 2 [/SUP], Goundappa K Balasubramani[SUP] 2 [/SUP], Emily T Martin[SUP] 3 [/SUP], Manjusha Gaglani[SUP] 4 [/SUP], H Keipp Talbot[SUP] 5 [/SUP], Manish M Patel[SUP] 6 [/SUP], Jill M Ferdinands[SUP] 6 [/SUP], Richard K Zimmerman[SUP] 1 2 [/SUP], Fernanda P Silveira[SUP] 1 2 [/SUP], HAIVEN Study Investigators
Affiliations
Abstract
Background: Yearly influenza immunization is recommended for immunocompromised (IC) individuals, although immune responses are lower than that for the non-immunocompromised and the data on vaccine effectiveness (VE) in the IC is scarce. We evaluated VE against influenza-associated hospitalization among IC adults.
Methods: We analyzed data from adults ≥ 18 years hospitalized with acute respiratory illness (ARI) during the 2017-2018 influenza season at 10 hospitals in the United States. IC adults were identified using pre-specified case-definitions, utilizing electronic medical record data. VE was evaluated with a test-negative case-control design using multivariable logistic regression with PCR-confirmed influenza as the outcome and vaccination status as the exposure, adjusting for age, enrolling site, illness onset date, race, days from onset to specimen collection, self-reported health, and self-reported hospitalizations.
Results: Of 3,524 adults hospitalized with ARI, 1,210 (34.3%) had an immunocompromising condition. IC adults were more likely to be vaccinated than non-IC (69.5% vs 65.2%), and less likely to have influenza (22% vs 27.8%). The mean age did not differ among IC and non-IC (61.4 vs 60.8 years old). The overall VE against influenza hospitalization, including immunocompetent adults, was 33% (95% CI, 21% to 44%). VE among IC vs non-IC adults was lower at 5% (-29% to 31%) vs. 41% (27% to 52%) (p<0.05 for interaction term).
Conclusions: VE in one influenza season was very low among IC individuals. Future efforts should include evaluation of VE among the different immunocompromising conditions and whether enhanced vaccines improve the suboptimal effectiveness among the immunocompromised.
Keywords: immunocompromised; influenza; vaccine; vaccine effectiveness.
. 2021 Jan 3;ciaa1927.
doi: 10.1093/cid/ciaa1927. Online ahead of print.
Effectiveness of Influenza Vaccine for Preventing Laboratory-Confirmed Influenza Hospitalizations in Immunocompromised Adults
Kailey Hughes[SUP] 1 [/SUP], Donald B Middleton[SUP] 1 2 [/SUP], Mary Patricia Nowalk[SUP] 2 [/SUP], Goundappa K Balasubramani[SUP] 2 [/SUP], Emily T Martin[SUP] 3 [/SUP], Manjusha Gaglani[SUP] 4 [/SUP], H Keipp Talbot[SUP] 5 [/SUP], Manish M Patel[SUP] 6 [/SUP], Jill M Ferdinands[SUP] 6 [/SUP], Richard K Zimmerman[SUP] 1 2 [/SUP], Fernanda P Silveira[SUP] 1 2 [/SUP], HAIVEN Study Investigators
Affiliations
- PMID: 33388741
- DOI: 10.1093/cid/ciaa1927
Abstract
Background: Yearly influenza immunization is recommended for immunocompromised (IC) individuals, although immune responses are lower than that for the non-immunocompromised and the data on vaccine effectiveness (VE) in the IC is scarce. We evaluated VE against influenza-associated hospitalization among IC adults.
Methods: We analyzed data from adults ≥ 18 years hospitalized with acute respiratory illness (ARI) during the 2017-2018 influenza season at 10 hospitals in the United States. IC adults were identified using pre-specified case-definitions, utilizing electronic medical record data. VE was evaluated with a test-negative case-control design using multivariable logistic regression with PCR-confirmed influenza as the outcome and vaccination status as the exposure, adjusting for age, enrolling site, illness onset date, race, days from onset to specimen collection, self-reported health, and self-reported hospitalizations.
Results: Of 3,524 adults hospitalized with ARI, 1,210 (34.3%) had an immunocompromising condition. IC adults were more likely to be vaccinated than non-IC (69.5% vs 65.2%), and less likely to have influenza (22% vs 27.8%). The mean age did not differ among IC and non-IC (61.4 vs 60.8 years old). The overall VE against influenza hospitalization, including immunocompetent adults, was 33% (95% CI, 21% to 44%). VE among IC vs non-IC adults was lower at 5% (-29% to 31%) vs. 41% (27% to 52%) (p<0.05 for interaction term).
Conclusions: VE in one influenza season was very low among IC individuals. Future efforts should include evaluation of VE among the different immunocompromising conditions and whether enhanced vaccines improve the suboptimal effectiveness among the immunocompromised.
Keywords: immunocompromised; influenza; vaccine; vaccine effectiveness.